Constitutive activating mutations of the TSHR gene, have been detected in about 30 per cent of hyperfunctioning human thyroid adenomas and in a minority of dierentiated thyroid carcinomas. The mutations activating the TSHR gene(s) in the thyroid carcinomas, were located at the codon 623 changing an Ala to a Ser (GCC?TCC) or in codon 632 changing a Thr to Ala or Ile (ACC?GCC or ACC?ATC). In order to study if the constitutively activated TSHR gene(s) has played a role in the determination of the malignant phenotype presented by these tumors, we investigated: (1) the transforming capacity after transfection of mouse 3T3 cells, of a TSHR cDNA activated by an Ala?Ser mutation in codon 623 or an Thr?lle mutation in codon 632 and (2) the pathway(s) eventually responsable(s) for the malignant phenotype of the cells transformed by these constitutively activated TSHR cDNAs. Our results show that (1) the TSHR M623 or M632 cDNAs give rise to 3T3 clones presenting a fully neoplastic phenotype (growth in agar and nude mouse tumorigenesis); this phenotype was weaker in the cells transformed by the 632 cDNA; (2) suggest that the fully transformed phenotype of our 3T3 cells, may be the consequence of the additive eect of the activation of at least two dierent pathways: the cAMP pathway through G as and the Ras dependent MAPK pathway through G bg and PI3K and (3) show that the PI3K isoform playing a key role as an eector in the MAPK pathway activation in our 3T3-transformed cells is PI3Kg. Signaling from PI3Kg to MAPK appears to require in our murine cellular system a tyrosine kinase (still not characterized), Shc, Grb2, Sos, Ras and Raf. It is proposed that the constitutively activated TSHR genes detected in the thyroid carcinomas, may have played an oncogenic role, participating in their development through these two pathways. Oncogene (2000) 19, 4896 ± 4905.
Introduction
G protein coupled receptors (GPCR) share a common seven-transmembrane domain structure, although they respond to chemically distinct stimulants (Dohlman et al., 1987) . Their structural convergence is presumed to be the basis of their common mechanism, which is to translate extracellular ligand binding into intracellular activation of one or more species of heterotrimeric G proteins (Birnbaumer et al., 1990) . Such receptors mediate an enormous variety of biological actions, and their role in mitogenesis has been suspected for sometime as well as the possibility that they could be involved in abnormal growth and even in cancer (Sharif et al., 1994) . Discovery of the mas oncogene by transfection of tumor cell DNA into NIH3T3 ®broblasts, has been the ®rst link between cellular transformation and GPCRs (Gutkind, 1998) . This result predicted that other GPCRs would be found that could elicit malignant transformation. Indeed, using in vitro transfection assays into mouse ®bro-blasts, it has been also shown that the 5HT1c and the multiple muscarinic acetylcholine receptors had a transforming activity when activated by their agonists (Gutkind, 1998) . Subsequently, Allen et al. (1991) and Kjelsberg et al. (1992) showed that a GPCR constitutively activated by mutation, was also able to transform cells in vitro: the a 1B -adrenergic receptor.
The thyroid stimulating hormone receptor (TSHR) is a member of the GPCRs family and its activation represents the principal mechanism by which TSH regulates both proliferation and dierentiation in thyroid tissue through the G-protein-adenylate cyclase (AC) system (Dumont et al., 1989) . Genetically constitutive activation of this cAMP transducing pathway may act as an oncogenic mechanism in thyroid tumorigenesis. Indeed, constitutive activation by point mutations of the G as protein (gsp) and the TSHR genes, has been found in thyroid hyperfunctioning adenomas (Lyons et al., 1990; Parma et al., 1993; Russo et al., 1995a; SaõÈ d et al., 1994; SuaÂ rez et al., 1991) . These observations implicate the G as protein subunit and its linked cell surface TSHR in hyperproliferative diseases, including perhaps cancer. In this context it is interesting to point out that TSHR mutations were also described by us in codon 623 changing an Ala to a Ser (GCC?TCC) and Spambalg et al. in codon 632 changing a Thr to Ala or Ile (ACC?GCC or ACC?ATC), in some dierentiated thyroid carcinomas (Russo et al., 1995b; Spambalg et al., 1996; SuaÂ rez et al., 1991) . The carcinomas studied in our laboratory presented increased basal levels of cAMP and a poor response to TSH, mimicking the phenotype of a hyperfunctionning adenoma (Russo et al., 1995b; SuaÂ rez et al., 1991) . Unfortunately, such parameters were not analysed in the carcinomas studied by Spambalg et al. (1996) . These latter data raises the question of whether, the stimulation of the cAMP pathway was alone responsable for the highly agressive and malignant phenotype showed by our thyroid carcinomas. Based on recent results showing Ras involvement in all forms of surface receptor mitogenic action (Sharif et al., 1994; Gutkind, 1998) , it is actually accepted that a pathway from GPCRs to Ras activation may exist. Malignant transformation by GPCRs may be a process requiring the participation of the three sub-units of Gs proteins, the choice of the dierent targets being perhaps in¯uenced by the level of expression of each subunit and/or the intensity and duration of its activation. An activated G protein may in this context elicit either cAMP or Ras stimulation, or alternatively, both simultaneously.
Recent work has also revealed that the family of extracellular signal-regulated kinases (ERKs) or mitogen-activated kinases (MAPKs), are important components of the intracellular signaling pathway(s) controlling cell proliferation (Marshall, 1995) , and that constitutive activation of molecules upstream of the MAPK pathway is sucient for tumorigenesis (Mansour et al., 1994) . Indeed, GPCRs activate MAPKs in a multistep process (Lopez-Ilasaca et al., 1997) . The emerging picture is that agonist activated GPCRs ®rst cause the exchange of GDP bound to G a for GTP, thereby causing the dissociation of G bg from GTP bound G a . Free G bg would then recruit PI3Kg to the plasma membrane, enhancing the activity of a Src-like kinase, which in turn leads to the activation of the Shc ± Grb2 ± Sos ± Ras pathway, resulting in increased MAPK activity.
In order to try to understand the eventual role played by constitutively activated TSHR gene(s) in the determination of a benign or malignant phenotype in human thyroid tumors, we investigated: (1) the transforming capacity after transfection of mouse 3T3 cells, of expression vectors bearing a TSHR cDNA activated by a point mutation, and (2) whether the point mutation constitutively activated TSHR gene, acts as an oncogene, thereby enhancing the activity of normal signaling pathway(s) which may result in the establishment of the malignant phenotype of transformed cells, independently of agonist supplementation. Figure 1 , after hybridization with the BSK/ TSHR probe: (1) no band was observed in the control 3T3 cells and (2) a band of about 2.3 Kb corresponding to the TSHR transcript was detected in all transformant cell lines. This transcript was signi®cantly more abundant in the two clones transformed by the TSHR M623 plasmid than in the TSHR
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-transformed and TSHR-WT clones. The WT transcript was the less abundant one.
We rehybridized the Northern blot to a murine actin probe, and as shown in the ®gure, this control con®rms that the variations in the quantity of the transcripts between the dierent cell lines, were not due to inecient selection, poor transfer or RNA degradation.
We further characterized our TSHR-M-transformed cells and data presented in Table 1 show that: (1) the TSHR M623 cells presented a transformed malignant phenotype. They were able to grow in agar with a cloning eciency varying between 0.1 and 0.08% depending on the clone. When nude mice were inoculated subcutaneously with 2610 6 transformed cells, the animals developed tumors within 3 ± 4 weeks and (2) the TSHR M632 cells also presented a transformed malignant phenotype, but weaker than the M623 cells. Indeed, they were able to grow in agar but with a lower eciency and produced smaller colonies than the M623 cells and only one animal developed a tumor after 6 weeks. Figure 2a and data not shown). On the contrary, it was observed in the transformed untreated cells. This MAPK activity was stimulated after thyroid stimulating hormone (TSH) or epidermal growth factor (EGF) treatment and after transfection of a mutationally activated form of MEK (MEK-E). The basal and stimulated MAPK activity, was higher in the 3T3/TSHR-M623 cells ( Figure  2a) . Wortmanin an inhibitor of PI3Ks, diminished MAPK activity in all the samples with the exception of the EGF-stimulated and MEK-transfected ones ( Figure  2a ). These latter data were similar in both of the TSHR-M-transformed clones.
Taking into account the data presented above, we decided to follow-up our study using only the M623 -transformed cells.
We also investigated the role eventually played by G bg subunits and the guanine nucleotide exchange factor SOS, in the MAPK activation observed in our 3T3/TSHR M623 transformed cells. The cells were transfected with expression plasmids for G b1 and G g2 alone, or together with a plasmid for SOS, and with a membrane-targeted form of SOS (myr-SOS) alone, in the presence or absence of wortmanin ( Figure 2b ). MAPK activity induced by G bg or by coexpression of G bg with SOS was inhibited by wortmanin. In contrast, no eect of wortmanin in 32 P incorporation in myelin basic protein (MBP) was observed in the myr-SOS transfected samples (Figures 2b and 3c ). Altogether these results, suggest a role for PI3K in the MAPK activation induced by the TSHR-M cDNA integrated The cells were incubated for 1 h at 378C without (control) or with the indicated doses of TSH in the presence of HEPES (20 mmol/l; pH 7.4), 1.5% BSA and isobutylmethylxanthyne (1 mmol/l). cAMP assay was performed as described by Russo et al. (1995a) . cDNA, TSH, EGF or MEK E. Forty-eight hours after transfection of subcon¯uent cells with the expression plasmids of HA-MAPK or MEK E, 3T3/TSHR-transformed cells were treated for 5 min with TSH or EGF (150 ng/ml) in the presence or absence of wortmanin (which was added 30 min before) and MAPK activity was assayed in cellular lysates (Lopez-Ilasaca et al., 1997) (b) action of wortmanin on MAPK activation induced by Gbg. 3T3/TSHR M623 cells were transfected (or not : C sample) with G-protein subunits expression plasmids (G b1 and G g2 ) alone or together with Sos or myrSos. Forty-eight hours after transfection, wortmanin treatment was carried out for 30 min and MAPK activity was assayed as indicated (Lopez-Ilasaca et al., 1997) in the 3T3-transformed cells. This signal transduction proceeds separately from the EGF pathway and upstream of SOS and MEK.
MAPK is activated in 3T3/TSHR-M-transformed cells through PI3Kg
To determine which of the PI3K isotypes known at present (PI3Ka, b or g) (Marshall, 1995) , induces the MAPK activation, we expressed the a and g forms in 3T3/TSHR M623 cells. PI3Kg induced a stimulation of MAPK activity which was concentration dependent (Figure 3a) . The MAPK activity did not vary after expression of PI3Ka or a mutant of PI3Kg lacking lipid kinase activity [PI3KgK799R(DK)] (Figure 3b and c) and the stimulation of MAPK by PI3Kg was abolished by wortmanin ( Figure 3c ). These results show that PI3Kg may mediate the wortmanin-sensitive activation of MAPK observed in the 3T3/TSHR M623 cells.
The MAPK stimulation induced by G bg is signi®-cantly reduced by co-transfection with the PI3Kg-mutated expression vector (Figure 4 ). This inhibitory eect is also observed, but at a lower degree, in the MAPK permanent activation induced in 3T3-transformed cells by the integrated TSHR M623 plasmid. On the contrary, no eect is exerted after stimulation of MAPK by EGF (Figure 4) . Moreover, it has been also observed by others that this PI3Kg mutant, is unable to inhibit PLC-b 2 activation induced by co-transfection of Cos cells with the muscarinic receptor m2 and G bg (Lopez-Ilasaca et al., 1997) . All these data suggest that the inhibitory eect of PI3Kg-deleted DK plasmid, is speci®c for the MAPK response to G bg as well as for other bg stimulated pathways.
Role of PI3Kg in the MAPK signaling pathway
With the aim of studying how PI3Kg induces the MAPK stimulation observed in our 3T3/TSHR M623 -transformed cells, we used a chimeric molecule composed of the extracellular and transmembrane domain of CD8 fused to the COOH-terminal domain of BARK, which includes the bg-binding region (Lopez-Ilasaca et al., 1997) . This molecule which express the CD8 antigen at the cell surface and the BARK COOH-domain at the inner face of the plasma membrane, is able to block bg-dependent pathways (i.e. Subcon¯uent 3T3/TSHR M623 cells were transfected with the empty vector and expression plasmids for G bg or PI3Kg-DK and MAPK activity was determined 48 h later as described by Lopez-Ilasaca et al. (1997) Oncogene PLC-b 2 activation by G bg ) after ®xation of free bg (Lopez-Ilasaca et al., 1997). As shown in Figure 5 , coexpression of CD8-BARK with PI3Kg signi®cantly reduced MAPK activation in the 3T3-transformed cells, whereas a control CD8 expression vector did not. However, when CD8-BARK was co-transfected with myr-PI3Kg, a construction bearing the PI3Kg coding region fused to the NH 2 -terminal myrostilation membrane localization sequence from c-Src (LopezIlasaca et al., 1997), there was no inhibition of the stimulation of MAPK activity. These results suggest that PI3Kg is localized in the plasma membrane by G bg , playing a role of linker between the TSHR-M cDNA product and the G protein sub-units in the MAPK pathway.
Role of other molecules in MAPK activation
In order to study the role of dierent molecules in signal transduction from PI3Kg to MAPK cascade in 3T3/TSHR
M623
-transformed cells, we tested negative mutants of Ras, Rho A, Rac, Cdc42 and Raf, as well as a mutant Sos expression vector coding for a protein lacking the domain involved in Ras-speci®c guanine nucleotide exchange activity (SosDcdc25).
The dominant negative mutants N17-Ras and DNRaf and the mutant SosDcdc25 inhibit the basal MAPK activity observed in the control cells, as well as that induced by PI3Kg. On the contrary, no eect was observed in the DK or MEK-E transfected cells (Figure 6a ± c) . The negative mutants of RhoA, Rac and Cdc42 are unable to suppress the basal MAPK activity observed in the control cells, or the MAPK stimulation induced by PI3Kg or the TSH ligand (data not shown).
To exclude the possibility that the experiments cited above re¯ect the requirement for one or more of Ras downstream pathways other than MAPK in the process of transformation, we also studied the eect of an speci®c pharmacological inhibitor of MAPK: PD98059 (Gire et al., 1999) on the basal MAPK activity observed in the 3T3/TSHR M623 cells. MAPK activity was inhibited by PD98059 in a dose dependent manner, excluding eects of the eectors on alternative pathways (Figure 7a ). Moreover, PD98059 treatment was associated with a signi®cant reduction in cloning eciency of 3T3/TSHR M623 cells in agar (Table 3) . We also investigate the eventual participation of Shc and Grb2 in the MAPK stimulation observed in our cells. These molecules of the receptor tyrosine kinasestimulating signaling cascade, participate in G bgdependent signal transduction (Van Biesen et al., 1995) . As shown in Figure 7B 
Effect of the N17 negative mutant of Ras on the phenotype of TSHR-M-transformed 3T3-Vill cells
To follow up the data described above, we decided to study the eect of wortmanin and the N17 dominant negative Ras mutant on the phenotype of our TSHR M623 -transformed 3T3 cells. Indeed, our TSHR M623 and M632 -transformed ®broblasts showed a p21 Ras overexpression, which was proportional to the expression of the TSHR activated cDNAs show in Figure 1  (Figure 8 ). This overexpression was not due to an activating point mutation in the Ras critical codons (data not shown).
The 3T3`normal' or TSHR-M-transformed cells were treated with wortmanin or transfected with the N17 plasmid, as described in Materials and methods, and cultured in soft agar. Parallel cultures of untreated or untransfected cells, were also cultured in soft agar. As shown in Table 3 : (a) control 3T3 cells do not grow in agar in the presence or absence of wortmanin or the N17 plasmid; (b) wortmanin reduces the number of colonies in agar by a factor 4 or 3 for TSHR-M Cl1 or TSHR-M Cl2 respectively and (c) N17 completely inhibit the formation of Cl1 and Cl2 colonies in agar.
To eliminate the possibility of an eventual toxic eect of N17 on 3T3/TSHR M623 -transformed cells, 3T3/ v-Raf-transformed cells were transfected with a similar Total number of colonies in 10 petri dishes after 4 weeks. b 10 6 3T3-Vill or TSHR-M cells were seeded in 75 cm 2 culture¯aks. Twenty-four hours later they were treated for 24 h with PD98059 (60 mM). After three washings the cells were trypsinized and cultured in soft agar as described (Michelin et al., 1991) . c 10 6 3T3-Vill or TSHR-M cells were seeded in 75 cm 2 culture¯asks. Twenty-four hours later they were treated for 30 min with 100 nM of Wortmanin. After three washings the cells were trypsinized and cultured in soft agar in 6 cm petri dishes, as described (Michelin et al., 1991) . .5) concentration of the dominant negative Ras mutant. No signi®cant reduction in the number of colonies in agar was observed in the v-Raf-transformed cultures, suggesting that the capacity of 3T3/TSHR M623 cells to grow in a semi-solid media is Ras-dependent and completely inhibited by N17 mutant.
Discussion
Our present data shows ®rst that a TSHR gene constitutively activated by point mutation in codons 623 or 632, can act as a transforming oncogene for 3T3 mouse cells independently of its ligand, and that the transformed cells show a stimulated cAMP pathway. The stimulation of the cAMP pathway was lower and the transformed phenotype was weaker in the M632 -transformed cells. Similar results have been obtained also by Allen et al. (1991) with an a 1B -adrenergic receptor constitutively activated by point mutation after transfection of 3T3 mouse or rat ®broblasts. However, in this publication there was no study of the signalling pathway(s) in the transformed cells.
Permament activation of the AC pathway has been described in congenital hyperthyroidism after mutation of the TSHR gene (Duprez et al., 1994; Tonacchera et al., 1996) as well as in thyroid hyperfunctioning adenomas bearing a mutated G as subunit or TSHR gene (Freissmuth and Gilman 1989; Landis et al., 1989; Parma et al., 1993; Russo et al., 1995a) . In addition, it has also been shown that the expression of a mutated G as or TSHR protein, was able to induce in FRTL-5 rat thyroid cells, TSH-independent proliferation (FourneÂ s et al., 1998). The development of hyperfunctioning adenomas in transgenic mice has also been observed after expression of a G as mutated transgene (Michiels et al., 1994) . On the contrary, until now there has been no report of the induction of a fully neoplastic transformed phenotype in vivo or in vitro by either a mutationally activated G as or by a TSHR wild type genes (FourneÂ s et al., 1998; Russo et al., 1995a; SaõÈ d et al., 1994) .
The majority of the thyroid tumors in which a mutated G as or TSHR gene were detected, are benign and not malignant. Is it the consequence of a level of expression which is sucient to activate the AC(s) isoforms originating a benign tumor (adenoma), but is not sucient to induce also the activation of other pathways which may give rise perhaps to a more agressive tumor (carcinoma)? It is actually clear that both, activated Ga and free bg subunits can stimulate dierent eector pathways and that the activated GPCRs activate MAPKs through the bg heterodimers but not the Ga subunit (Gutkind, 1998) . Taking into account these data, we decided to investigate whether pathways other than the cAMP one (i.e. MAPK), participated (or were activated) in the process of malignant transformation by the TSHR M623 cDNA of our 3T3 mouse cells. This cellular model was prefered to the TSHR M632 transformed one, because of its stronger transformed phenotype.
We ®rst showed that there was a basal MAPK activation in 3T3/TSHR-M cells, when compared to the normal 3T3 cells, which was stimulated by PI3Kg in a Gbg dependent fashion. Signaling from PI3Kg to MAPK appears to require a tyrosine kinase, Shc, Grb2, SOS, Ras and Raf. The basal MAPK activation in 3T3/TSHR M623 cells was inhibited by PD98059 an speci®c pharmacological inhibitor of MAPKK, excluding action of the eector(s) on alternative pathways downstream of Ras (Gire et al., 1999) . Our data : (1) con®rm the critical role played by PI3Kg in linking GPCRs and Gbg to the MAPK signaling pathway in dierent cellular systems (Crespo et al., 1994; Gutkind, 1998; Lopez-Ilasaca et al., 1997) , and (2) are in accordance with the hypothesis previously suggested by others (Lopez-Ilasaca et al., 1997) that a tyrosine kinase (still not characterized) which may be required by PI3Kg for the stimulation of MAPK, phosphorylates Shc inducing its association with Grb2 and leading to a Ras dependent activation of MAPK.
This cascade mechanism, may be a common one for stimulation of MAPK by GPCRs in dierent cellular systems. The PI3Kg molecule is not stimulated by tyrosine phosphorylation but by physical interaction with Gbg complexes (Stoyanov et al., 1995) . It exerts its action upstream of Src-like kinases and Shc, Grb2, SOS and Ras, which may imply that heterotrimeric G proteins could regulate non-receptor protein tyrosine kinases and through them control the MAPK pathway (Gutkind, 1998) and perhaps, in some cases, modulate the degree of cellular transformation. Indeed, it seems to be the case in our TSHR M623 and TSHR M632 cells (see below).
As cited above, it is actually known that the activation of GPCRs leads to the activation of dierent signaling pathways, mainly in their natural setting (i.e. cAMP and MAPK). Perhaps in some cases the constitutive activation of the TSHR gene (or other GPCRs) by a point mutation may give rise not only to a cAMP pathway stimulation through G as , but also to dierent degrees of a Ras dependent MAPK activation mediated by G-protein bg subunits through PI3K. In this case the location of the mutation in the gene may play an important role. Indeed, the transformed phenotype as well as the levels of THSR mRNA and cAMP, were not the same in TSHR M623 or M632 -transformed cells. Both were stronger or higher in the 3T3/TSHR M623 cells. As predicted by in vitro mutagenesis (Chazenbalk et al., 1990 (Chazenbalk et al., , 1991 SchoÈ neberg et al., 1999) , the third intracellular loop in which the 623 mutation is located, plays a more critical role in Gprotein activation than the VI transmembrane domain where the 632 mutation occurs. Moreover, the substitution of an Ala by a Ser in codon 623 represents a major change in the protein structure, because a polar amino acid which is a potential target for phosphorylation substitutes for a neutral one. These molecular changes may provide in the transformed cells a very strong signal, resulting not only in a growth advantage by the stimulation of both the cAMP and MAPK pathways, but also a higher degree of activation by Ras of phenotypic characteristics not currently expressed by a normal cell (growth in agar and tumorigenicity). It may eventually explain also the particular aggressiveness shown by the TSHR M623 positive dierentiated thyroid carcinomas studied by us (Russo et al., 1995b) , and the higher malignant phenotype showed by the 3T3/TSHR M623 -transformed mouse ®broblasts. In this context it must be remembered that thyroid toxic nodules in which mutations aecting the TSHR-G as -cAMP pathway are present, only rarely (or never) progress toward malignancy, and that the thyroid carcinomas in which we detected an activated TSHR gene, also carried a Ras gene activated by point mutation or by overexpression (Russo et al., 1995b) . The MAPK pathway, unhappily, was not studied in these tumors. Indeed, as cited in Results, in our 3T3/TSHR M623 or M632 cells we detected an overexpression of the Ras p21 protein which was signi®cantly higher in the 623 clones and which was not the consequence of an activating point mutation in the`critical' codons of their Ha-, Ki-or N-ras genes. Our data indicate the key role played by PI3Kg and Ras in the process of cell proliferation and/or transformation of 3T3-Vill cells: the former stimulating cellular division through the MAPK pathway in cooperation with cAMP and perhaps with other yet unknown signaling networks and/or molecules, and the latter being not only at the origin of the MAPK activation but also determining the fully neoplastic transformed phenotype of 3T3 mouse cells. Indeed, while PD98059 and wortmanin only diminished the number of 3T3/TSHR-M colonies in agar, the N17 Ras negative dominant mutant completely abolished their growth.
The participation of the MAPK pathway and Ras in the process of cell proliferation and/or transformation, has also been studied in other laboratories using dierent cellular systems. These studies suggested that the requirement for single or multiple Ras signal pathways varies with respect both to the phenotypic parameter being assayed and the cellular system. For example in NIH3T3 cells activation of MAPK alone appears sucient to mimic the ability of mutant Ras to confer growth factor and anchorage independence but not focus forming ability (Cowley et al., 1994; Khosrasi-Far et al., 1996) . Work from Miller et al. (1998) and Cass et al. (1999) using Wistar rat thyroid cells, showed that TSH growth independence can be induced by activation of the PI3K-Ras and/or either the Ral-GDS efector pathways. These latter experiments also suggested a cross-talk between the cAMP and MAPK pathways, the stimulation or inhibition of MAPK phosphorylation and cell growth depending on the Ras eector mutant expressed. Furthermore, using human thyroid primary epithelial cells, Gire et al. (1999 Gire et al. ( , 2000 showed that: (1) Raf/MAPK pathway is necessary, but not sucient for Ras induced proliferation; (2) mutant (V12) Ras activates the PI3K pathway; (3) activation of PI3K is necessary for Ras induced proliferation, and (4) PI3K activation, though not sucient alone, can synergize with activation of MAPK to mimic Ras-induced proliferation. The PI3K isoform implicated in proliferation, was not determined in the above experiments. These and our present data, show that PI3K is absolutely necessary as a linker and an eector in the proliferative response to MAPK activation. Furthermore, it has been suggested that in primary human epithelial cells the proliferative response to Ras, is the consequence of the suppression by PI3K of Ras-induced apoptosis (Gire et al., 2000) . Whether or not this is also the case in other cellular systems, must be determined.
In this context, it is interesting to point out that preliminary results from our laboratory using expression vectors which stimulate individual parts of the MAPK pathway suggest that in our cellular murine system, the activated MAPK pathway alone seems to be sucient to induce a transformed phenotype. However, this transformed phenotype is weaker than that induced by the TSHR M623 plasmid (lower eciency of transformation and smaller colonies) (unpublished results). These preliminary results if con®rmed, together with the data cited above from our and other laboratories, will strengthen the importance in our 3T3 murine system of a cooperation between the activated cAMP and MAPK pathways to lead to a fully malignant phenotype.
In conclusion, the fully transformed and malignant phenotype of our 3T3/TSHR-M cells may be the consequence of the additive eect of the activation by the codons 623 and 632 mutated TSHR cDNAs of at least two dierent pathways: the cAMP pathway through G as and the Ras dependent MAPK pathway through Gbg and PI3Kg. This activation may be higher in the 3T3/TSHR M623 cells. It is tempting to propose, taking into account however that our data have been obtained using murine ®broblasts, that the constitutively activated TSHR mutated genes detected by us and others in dierentiated thyroid carcinomas (Russo et al., 1995b; Spambalg et al., 1996) have played a similar role in the development of these tumors, acting as an oncogene through the activation of both the cAMP and MAPK pathways. Following a multistep model for thyroid carcinogenesis (SaõÈ d et al., 1994) , it can be postulated that a constitutive activation of the cAMP pathway may provide a growth advantage to a clone(s) already transformed by an activated Ras through the MAPK pathway and partially abolishing, through an unknown mechanism(s), the dierentiation induced in the transformed thyrocytes by cAMP. We cannot exclude the participation in this process, of other pathways and/or molecules.
Materials and methods
Cell culture
3T3-Vill mouse ®broblasts (SuaÂ rez et al., 1988) and transformants were grown in DMEM containing 10% newborn bovine serum. The test for colony formation in soft agar was performed following the procedure previously described (Michelin et al., 1991) . The cells were treated with the MAPKK inhibitor PD98059 as described by Gire et al. (2000) .
Expression plasmids
The cDNAs WT or M623 are inserted respectively, in the EcoRI or EcoRI ± XbaI sites of the pECE vector cloning site. The pECE is inserted in the BamHI site of the pSV2-neo plasmid (Russo et al., 1995a) . The cDNA M632 is inserted in the BamHI ± EcoRI site of the pCEV29 vector cloning site (Garcia et al., unpublished) . The pHa-ERK2, pPI3Kg, pPI3KgK799R(DK), pmyrPI3Kg, pCDM8-g2, pCDM8-b1, pMEK-E, pCEVCD8, pCEVCD8BARK, pCEVP100a, pRAFK 375 W (DNRAF), pN17RAS, pN17RAC1, pPAN19Rho, pN17cdc42, pmyr-SOS, pSOSDcdc25, pShcY317F and pFYNC plasmids, have been previously described (Lopez-Ilasaca et al., 1997) .
DNA transfection
Subcon¯uent cells were transfected with 10 mg of the TSHR wild type or mutated recombinant expression plasmids, by the calcium phosphate precipitation method, as described (Michelin et al., 1991) . The quantities of DNA transfected for the other plasmids varied depending on the experiments. For the focus formation assays, 24 h after transfection the cells were trypsinized, split 1 : 10 and cultured in the presence of DMEM, 5% newborn bovine serum. Cultures were changed twice a week with fresh medium, and the foci scored after 4 weeks of culture. The colonies obtained with the TSHR-M cDNAs were cloned and cultured as described (Michelin et al., 1991) . For selection of clones after transfection with TSHR-WT cDNA, cells were cultured in the presence of the neomycin analogue G418 sulfate (400 mg/ml) (Gibco Brl Life Technologies).
RNA extraction and Northern blots
After extraction of total cellular RNA, Poly A RNAs were isolated as previously described (Michelin et al., 1991) . For Northern blot hybridization with the labeled BSK/TSHR probe (a gift of Dr M Misrahi, HoÃ pital de BiceÃ tre, France) or PAL41 mouse b actine probe, we utilized the technique previously described (Michelin et al., 1991) .
Cellular cAMP measurements
Cells in 2 cm 2 dishes (Costar Corp., Cambridge, MA, USA) were incubated with fresh Ham's F-12 medium containing 1.5% BSA, 1 mmol/l isobutylmethylxantine, 20 mmol/l HEPES (pH 7.4) and supplemented with increasing doses of TSH (Thytropar, Armour Pharmaceutical Co., Phoenix, AZ, USA). After 1 h at 378C, cellular cAMP was extracted with 95% ethanol and measured as previously described. The values were corrected for the DNA content of the wells, assessed as previously described (Russo et al., 1995a) .
MAPK assay
For the MAPK assay we used the technique described by Lopez Ilasaca et al. (1997) . Phosphorylated MBP was visualized by autoradiography and quanti®ed with either a phosphorimager or a liquid scintillation detector. Parallel samples were immunoprecipitated with antibody to epitope tagged MAPK (HA) and processed for protein immunoblot analysis with a MAPK-speci®c antiserum (Lopez-Ilasaca et al., 1997) .
Protein immunoblot analysis
Lysates of total cellular protein or anti-HA immunoprecipitates were analysed by protein immunoblotting after SDS ± PAGE with the corresponding rabbit antiserum or mouse mAB (Lopez-Ilasaca et al., 1997) . Immunocomplexes were visualized by enhanced chemiluminiscence detection (Amersham) with the use of goat antiserum to rabbit or mouse immunoglobulin G coupled to horseradish peroxidase (Cappel, West Chester, PA, USA) (Lopez-Ilasaca et al., 1997) . Mouse mABs to the HA epitope 12 CA5 were purchased from Babco. Rabbit polyclonal antisera to Shc and Grb2 were purchased from Santa Cruz Laboratories (Santa Cruz, CA, USA). For Ras we used the anti-pan-Ras Ab from Oncogene Science.
Tumorigenesis
3T3-Vill cells transformed or not, were trypsinized and washed and resuspended in PBS. The animals, nu/nu CD1 mice, were then injected with 2610 6 cells and monitored at weekly intervals for the development of tumors over a 4 ± 6 weeks period.
